Bone marrow aspirate injections didn't lead to significant changes for patients who had arthroscopic partial meniscectomy, according to a Sept. 15 study in The American Journal of Sports Medicine.
Biologics
Spine biologics is a realm ripe for exploration of its potential and applications in patient care.
Regenerative medicine in spine surgery is on the rise, and there are many biologic tools that physicians say could be used more in the field.
Temple Therapeutics, a women's health company, launched a spinoff venture for orthopedic sports medicine, according to a Sept. 9 news release.
Growing biologics portfolios will play a key role in pushing the spine surgery device market in the coming years, according to a report from Coherent Market Insights.
Advertisement
From product debuts and approvals, here are four key updates from orthobiologic companies since June 4.
LifeNet Health, in partnership with Johnson & Johnson MedTech, launched the PliaFX Pak bone allograft in the U.S., according to an Aug. 27 news release shared with Becker's.
Elutia, formerly Aziyo Biologics, has continued to face litigation related to spine biologics allegedly linked to tuberculosis infections that were recalled in recent years.
One of 10 former MiMedx employees involved in a noncompete lawsuit has filed counterclaims against the company.
Vericel earned FDA approval for a supplemental Biologics License Application, which will expand the company's Maci label to include arthroscopy, according to an Aug. 26 news release.